A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

NCT04556773 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Durvalumab
DRUG: Paclitaxel
DRUG: Capivasertib
DRUG: Anastrozole
DRUG: Fulvestrant
DRUG: Capecitabine

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]